ArticleJournal of cancer research and clinical oncology2023

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.

Karin G Schrenk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.